Human papillomavirus infection

Hutter, Jack; Decker, Catherine F.

doi:10.1016/j.disamonth.2016.03.014

Cited by 14 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are currently no available antiviral drugs targeting HPV infection . Recently, we generated an antiviral biologics termed REBACIN®, and it showed significant efficacy against HSVII viral infection in mouse (unpublished data).…”

Section: Introductionmentioning

confidence: 99%

“…There are currently no available antiviral drugs targeting HPV infection. 23 Recently, we generated an antiviral biologics termed REBACIN ® , and it showed significant efficacy against HSVII viral infection in mouse (unpublished data). In this article, we investigated REBACIN ® as a noninvasive clinical intervention and found its potential therapeutic efficacy against HPV persistent infection both in vivo and in vitro as well as in clinical trial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

Yang

Duan

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

The development of highly sensitive HPV‐genotyping tests has opened the possibility of treating HPV‐infected women before high‐grade lesions appear. The lack of efficient intervention for persistent high‐risk HPV infection necessitates the need for development of novel therapeutic strategy. Here we demonstrate that REBACIN®, a proprietary antiviral biologics, has shown potent efficacy in the clearance of persistent HPV infections. Two independent parallel clinical studies were investigated, which a total of 199 patients were enrolled and randomly divided into a REBACIN®‐test group and a control group without treatment. The viral clearance rates for the REBACIN® groups were 61.5% (24/39) and 62.5% (35/56), respectively, for the two independent parallel studies. In contrast, the nontreatment groups showed self‐clearance rates at 20.0% (8/40) and 12.5% (8/64). We further found that REBACIN® was able to significantly repress the expression of HPV E6 and E7 oncogenes in TC‐1 and Hela cells. The two viral genes are well known for the development of high‐grade premalignancy lesion and cervical cancer. In a mouse model, REBACIN® was indicated to notably suppress E6/E7‐induced tumor growth, suggesting E6 and E7 oncogenes as a potential target of REBACIN®. Taken together, our studies shed light into the development of a novel noninvasive therapeutic intervention for clearance of persistent HPV infection with significant efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

Yang

Duan

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Por ello, es el principal agente etiológico del cáncer de cérvix, el segundo cáncer más frecuente en mujeres alrededor del mundo (Hutter & Decker, 2016). La incidencia de cáncer de cérvix en las Américas es de 83 195 casos registrados en el informe del Institut Catalàd´Oncologia al 15 de enero de 2014, siendo la cuarta causa de cáncer más frecuente en mujeres y el segundo más común entre las mujeres de 15-44 años.…”

Section: Introductionunclassified

Caracterización clínica e histopatológica de la infección por Papiloma Virus humano de muestras de cérvix. Hospital Teodoro Maldonado Carbo “IESS” // Histopathological and clinical characterization of Human Papilloma Virus infection in cervical samples. Teodoro Maldonado Carbo “IESS”

Bedoya¹,

Sánchez-Giler²,

Zambrano³

et al. 2017

View full text Add to dashboard Cite

El Virus del Papiloma Humano (HPV), posee una predilección por los tejidos poliestratificados, con persistencia en capas basales, de allí que a partir de ello es el agente etiológico del cáncer de cérvix, principalmente. Este tipo de cáncer es el segundo más frecuente en mujeres, alrededor del mundo. El HPV es único agente infeccioso oncogénico que lo provoca. Se realizó un trabajo para determinar la prevalencia del virus en mujeres, utilizando técnicas de detección de ADN mediante PCR, en tiempo real, a partir de biopsia de cérvix, además de establecer las características histopatológicas y clínicas relacionadas. La prevalencia fue del 30,67%, la presentación histopatológica más frecuentemente infectada fue el Cáncer de cérvix y el in situ. Mientras más displásica es la histopatología del cérvix, más frecuente es la presentación del virus. Se demostró una asociación entre la exposición a la infección y la presencia de secreción vaginal blanquecina y la dispareunia. ABSTRACT Human Papilloma Virus (HPV) has a predilection for poly-stratified tissues, with persistence in the basal layers, hence mainly is the etiological agent of cervical cancer. Cervical cancer is the second most common cancer in women worldwide. HPV is unique oncogenic infectious agent that causes it. The objective of the study was to determine the prevalence of the virus in women, using DNA detection techniques through PCR, in real-time, from the cervical biopsy. In addition, the related histopathological and clinical characteristics were established. The prevalence was 30.67%, the most frequently infected histopathology presentation was cervical and in situ cancer. The more dysplastic the histopathology of the cervix, the more frequent the presentation of the virus. An association between exposure to infection and the presence of whitish vaginal discharge and dyspareunia was demonstrated.

show abstract

“…Human papilloma virus (HPV) is the most common STI in the US [21]. It is estimated that 14 million people are infected with HPV annually [22].…”

Section: Sexually Transmited Viral Infectionsmentioning

confidence: 99%

“…High-risk strains, especially, HPV types 16 and 18, are responsible for malignant lesions such as cervical, penile, vulvar, vaginal, anal and oropharyngeal cancers, and premalignant lesions such as cervical dysplasia. Low-risk strains are responsible for benign lesions such as anogenital warts, benign or low-grade cellular changes, and recurrent respiratory papillomatosis (RRP) [21].…”

Section: Sexually Transmited Viral Infectionsmentioning

confidence: 99%